Search Results

You are looking at 11 - 20 of 444 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Lee S. Schwartzberg and Sarah L. Blair

: AC, anthracycline/cyclophosphamide; CMF, cyclophosphamide/methotrexate/fluorouracil; doc, docetaxel; G-CSF, granulocyte colony-stimulating factor; pts, patients; T, paclitaxel; TC, docetaxel/cyclophosphamide; TCH, docetaxel

Full access

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

that demonstrated a survival improvement compared with gemcitabine monotherapy was gemcitabine in combination with nab-paclitaxel, with a median OS of 8.5 months versus 6.7 months for gemcitabine alone. 5 , 14 Currently FOLFIRINOX and gemcitabine with

Full access

Robert F. Ozols

Ozols RF . Intraperitoneal therapy in ovarian cancer: Time's up . J Clin Oncol 1991 ; 9 : 197 – 199 . 4 Markman M Bundy BN Alberts DS . Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high

Full access

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

tested these recommended regimens. 171 – 175 , 177 – 196 The most commonly-used regimen, paclitaxel 175/carboplatin, has been considered the standard postoperative chemotherapy for ovarian cancer for many years, so there are many studies in which it has

Full access

Tatjana Gavrancic and Yeun-Hee Anna Park

/mL). The patient was diagnosed with stage IV HAL and started on palliative chemotherapy with carboplatin/paclitaxel and sorafenib (400 mg orally twice daily), followed by palliative radiation to the vertebrae for a total dose of 30 Gy. After 2 cycles of

Full access

Margaret A. Tempero

become more effective with the use of newer, presumably more active regimens, in particular FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel. Based on their benefit in the metastatic setting, these

Full access

Cesar A. Santa-Maria, Maureen O’Donnell, Raquel Nunes, Jean L. Wright, and Vered Stearns

weekly paclitaxel, and all patients received dose-dense (every 2 weeks) doxorubicin and cyclophosphamide (AC). A number of studies have been reported since then, with some, but not all, showing improvements in pCR in the ICI-containing arms ( Table 1 ). 3

Full access

Presenter: Margaret A. Tempero

neuropathy.” Omitting bolus fluorouracil, reducing doses, eliminating drugs that cause excessive toxicity, and using chemotherapy holidays have been found to increase the tolerability of this regimen. Another frequently used regimen, nab-paclitaxel

Full access

Matthew A. Gubens and Marianne Davies

chemotherapy and pembrolizumab regimen in this setting in August 2018. Another key frontline immunotherapy option for patients with non-SCC NSCLC (especially those who are pemetrexed-ineligible) is the 4-drug regimen of atezolizumab/carboplatin/paclitaxel

Full access

Caitlin A. Hester, Giampaolo Perri, Laura R. Prakash, Jessica E. Maxwell, Naruhiko Ikoma, Michael P. Kim, Ching-Wei D. Tzeng, Brandon Smaglo, Robert Wolff, Milind Javle, Michael J. Overman, Jeffrey E. Lee, and Matthew H.G. Katz

radiographic evidence of acute pancreatitis ( Figure 1 ). Figure 1. Study flow diagram. Abbreviations: FOLFIRINOX, 5-fluorouracil/leucovorin/oxaliplatin/irinotecan; Gem/Nab-paclitaxel, gemcitabine + nanoparticle albumin–bound paclitaxel; PDAC